Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
66 hedge funds and large institutions have $76.2M invested in Cidara Therapeutics in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 6 closing their positions.
166% more call options, than puts
Call options by funds: $154K | Put options by funds: $58K
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 65 → 66 (+1)
0.06% more ownership
Funds ownership: 3.05% → 3.11% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
18% less capital invested
Capital invested by funds: $92.7M → $76.2M (-$16.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.35M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$943K |
| 3 |
Goldman Sachs
New York
|
+$517K |
| 4 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$445K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$433K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$720K |
| 2 |
Two Sigma Investments
New York
|
-$584K |
| 3 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$323K |
| 4 |
Jane Street
New York
|
-$161K |
| 5 |
Two Sigma Advisers
New York
|
-$128K |
CDTX Hedge Fund Activity: Q3 2020 in Review
66 of the 4,969 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2020, worth a combined $76.2M — down 18% from $92.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CDTX positions and 6 closed out — a net gain of 1 holder — while 24 added to existing stakes and 19 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.35M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $720K sold.
- 66 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2020, up from 65 in Q2 2020.
- Funds reported $76.2M of Cidara Therapeutics stock for Q3 2020, down 18% quarter-over-quarter.
- 7 funds opened new Cidara Therapeutics positions in Q3 2020 and 6 closed out, a net change of +1 holder.
- The largest Cidara Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $3.35M added.
- The largest Cidara Therapeutics seller in Q3 2020 was Tekla Capital Management, an estimated $720K sold.
Based on aggregated 13F filings for Q3 2020.